United Therapeutics Corporation announced its financial results for the first quarter ended March 31, 2025, reporting a 17% year-over-year increase in total revenues to $794.4 million. Net income for the quarter grew 5% to $322.2 million, with diluted earnings per share reaching $6.63, up 7% from the prior year.
The company's treprostinil franchise continued its strong performance, with total Tyvaso revenues increasing 25% to $466.3 million. Remodulin and Orenitram also contributed positively, with revenues growing 8% to $138.2 million and 14% to $120.7 million, respectively.
Research and development expenses increased, primarily due to $30.0 million in milestone payments for drug delivery device technologies and $6.6 million related to adjustments to contingent consideration obligations for manufactured organ projects. The company anticipates further progress in its innovation and revolution waves of growth, including the TETON 2 readout and the planned commencement of the UKidney clinical study.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.